Home > Oncology > Use of trastuzumab deruxtecan in breast cancer trials likely guided by inaccurate assays

Use of trastuzumab deruxtecan in breast cancer trials likely guided by inaccurate assays


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA Oncology
Reuters Health - 09/02/2022 - Standard assays for ERBB2 like the one being used in trials of trastuzumab deruxtecan (T-DXd) for breast cancer could lead to misassignment of patients with few or no copies of the protein, researchers say. They are likely inaccurate for immunohistochemistry (IHC) scores between 0 and 1+, according to a report in JAMA Oncology. "About 15% of breast cancer cases show amplification of the ERBB2 gene, (which) leads to more than one million copies of the HER2 protein in breast cancer cells. These patients have been successfully treated with trastuzumab for over 25 years," Dr. David Rimm of Yale School of Medicine in New Haven told Reuters Health by email. T-DXd has been successful in breast cancer cases that were not ERBB2-amplified, he said. However, "the assay designed to pick out the 15% of cases with more than 1 million copies of the protein does not work well to distinguish patient tumors with no copies of the protein from patie...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on